An ODE model for the HER2/3-AKT signaling pathway in cancers that overexpress HER2

Solomon Itani; Joe Gray; Claire J. Tomlin

An ODE model for the HER2/3-AKT signaling pathway in cancers that overexpress HER2

Solomon Itani, Joe Gray, Claire J. Tomlin

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

Abstract

Targeted drug therapies have proven very useful as cancer treatments, but some still demonstrate very little antitumor activity in certain cancers. A class of tyrosine kinase inhibitors (TKIs) that are unexpectedly inefficient in some cancers are those that target the human epidermal growth factor receptor (HER) family. This paper proposes a mathematical model of the HER signaling pathway for the study and treatment of cancers that overexpress. The goals of this paper are threefold. The first is to introduce an ODE model that agrees with the existing data over large time intervals, and the second is to use this model to understand the effects of applying certain drugs to such cancers. We finally use this model to determine a "steering-based" treatment scheme for cancers that overexpress HER2.

Original language	English (US)
Title of host publication	Proceedings of the 2010 American Control Conference, ACC 2010
Pages	1235-1241
Number of pages	7
State	Published - Oct 15 2010
Externally published	Yes
Event	2010 American Control Conference, ACC 2010 - Baltimore, MD, United States Duration: Jun 30 2010 → Jul 2 2010

Publication series

Name	Proceedings of the 2010 American Control Conference, ACC 2010

Other

Other	2010 American Control Conference, ACC 2010
Country/Territory	United States
City	Baltimore, MD
Period	6/30/10 → 7/2/10

ASJC Scopus subject areas

Control and Systems Engineering

Cite this

An ODE model for the HER2/3-AKT signaling pathway in cancers that overexpress HER2. / Itani, Solomon; Gray, Joe; Tomlin, Claire J.

Proceedings of the 2010 American Control Conference, ACC 2010. 2010. p. 1235-1241 5531034 (Proceedings of the 2010 American Control Conference, ACC 2010).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

@inproceedings{1b9a295d78fe4c77b0776b0caa4e94d4,

title = "An ODE model for the HER2/3-AKT signaling pathway in cancers that overexpress HER2",

abstract = "Targeted drug therapies have proven very useful as cancer treatments, but some still demonstrate very little antitumor activity in certain cancers. A class of tyrosine kinase inhibitors (TKIs) that are unexpectedly inefficient in some cancers are those that target the human epidermal growth factor receptor (HER) family. This paper proposes a mathematical model of the HER signaling pathway for the study and treatment of cancers that overexpress. The goals of this paper are threefold. The first is to introduce an ODE model that agrees with the existing data over large time intervals, and the second is to use this model to understand the effects of applying certain drugs to such cancers. We finally use this model to determine a {"}steering-based{"} treatment scheme for cancers that overexpress HER2.",

author = "Solomon Itani and Joe Gray and Tomlin, {Claire J.}",

year = "2010",

month = oct,

day = "15",

language = "English (US)",

isbn = "9781424474264",

series = "Proceedings of the 2010 American Control Conference, ACC 2010",

pages = "1235--1241",

booktitle = "Proceedings of the 2010 American Control Conference, ACC 2010",

note = "2010 American Control Conference, ACC 2010 ; Conference date: 30-06-2010 Through 02-07-2010",

}

TY - GEN

T1 - An ODE model for the HER2/3-AKT signaling pathway in cancers that overexpress HER2

AU - Itani, Solomon

AU - Gray, Joe

AU - Tomlin, Claire J.

PY - 2010/10/15

Y1 - 2010/10/15

N2 - Targeted drug therapies have proven very useful as cancer treatments, but some still demonstrate very little antitumor activity in certain cancers. A class of tyrosine kinase inhibitors (TKIs) that are unexpectedly inefficient in some cancers are those that target the human epidermal growth factor receptor (HER) family. This paper proposes a mathematical model of the HER signaling pathway for the study and treatment of cancers that overexpress. The goals of this paper are threefold. The first is to introduce an ODE model that agrees with the existing data over large time intervals, and the second is to use this model to understand the effects of applying certain drugs to such cancers. We finally use this model to determine a "steering-based" treatment scheme for cancers that overexpress HER2.

AB - Targeted drug therapies have proven very useful as cancer treatments, but some still demonstrate very little antitumor activity in certain cancers. A class of tyrosine kinase inhibitors (TKIs) that are unexpectedly inefficient in some cancers are those that target the human epidermal growth factor receptor (HER) family. This paper proposes a mathematical model of the HER signaling pathway for the study and treatment of cancers that overexpress. The goals of this paper are threefold. The first is to introduce an ODE model that agrees with the existing data over large time intervals, and the second is to use this model to understand the effects of applying certain drugs to such cancers. We finally use this model to determine a "steering-based" treatment scheme for cancers that overexpress HER2.

UR - http://www.scopus.com/inward/record.url?scp=77957821636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957821636&partnerID=8YFLogxK

M3 - Conference contribution

AN - SCOPUS:77957821636

SN - 9781424474264

T3 - Proceedings of the 2010 American Control Conference, ACC 2010

SP - 1235

EP - 1241

BT - Proceedings of the 2010 American Control Conference, ACC 2010

T2 - 2010 American Control Conference, ACC 2010

Y2 - 30 June 2010 through 2 July 2010

ER -

An ODE model for the HER2/3-AKT signaling pathway in cancers that overexpress HER2

Abstract

Publication series

Other

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this